Plain-English fact sheet
Thymosin beta-4
Also known as Tβ4, TB4, full-length thymosin beta-4, TB-500 (fragment marketed online)
Thymosin beta-4 and fragments marketed as TB-500 are not FDA-approved medicines, and evidence for popular recovery claims remains limited.
Quick answer
Thymosin beta-4 is a naturally occurring peptide involved in cell movement and tissue processes. Experimental full-length products and the TB-500 fragment marketed online should not be treated as proven or interchangeable therapies.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Thymosin beta-4?
Thymosin beta-4 is present in many tissues and has roles involving actin, cell movement, inflammation, and repair signaling.
TB-500 commonly refers to a shorter fragment marketed online. Evidence about full-length thymosin beta-4 cannot automatically be applied to that fragment or to an unverified product.
Why are people interested in it?
It is discussed for injury recovery, wound healing, heart repair, eye conditions, and athletic performance.
Much of the enthusiasm comes from mechanistic or preclinical research rather than proven clinical outcomes.
Current regulatory status
No thymosin beta-4 or TB-500 product is FDA approved for consumer recovery or performance uses. FDA has specifically described evidence gaps and potential risks for the thymosin beta-4 fragment used in compounding.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Topical and systemic tissue-repair applications in research settings
Evidence snapshot
There are early human studies in selected areas, but the broad recovery claims seen online are supported mainly by preclinical evidence.
Potential benefits being researched
- Preclinical research suggests roles in cell migration, blood-vessel formation, and tissue repair.
- Early studies do not establish a general injury-recovery or athletic-performance treatment.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- FDA notes potential immune reactions, aggregation, peptide impurities, and a lack of identified human exposure data for the TB-500 fragment in drug products.
- Systemic effects and long-term consequences are insufficiently understood.
- Online products add identity, purity, sterility, and labeling uncertainty.
What we still do not know
- Whether effects in models translate into improved human recovery
- How full-length thymosin beta-4 differs clinically from marketed fragments
- Long-term safety and effects on abnormal blood-vessel or cell growth
- Reliable dosing, product identity, and manufacturing quality—topics this site does not provide instructions for
Plain-English takeaway
Thymosin beta-4 is scientifically interesting, but online recovery claims run ahead of clinical proof. Full-length peptide, fragments, and marketed products are not automatically equivalent.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- 2ClinicalTrials.gov studies: thymosin beta 4
Current and completed registered clinical studies.
- 3PubMed research: thymosin beta 4 clinical trial
Peer-reviewed literature indexed by the National Library of Medicine.